CPT 96116, 96366, 96367, 95716, and 95720 — all subject to documentation-driven auto-downcode rather than outright denial, making the revenue loss invisible to standard reporting workflows.
The 2026 CPT updates to cognitive assessment, therapeutic infusion, and long-term EEG monitoring codes are generating accepted-but-underpaid claims in neurology practices whose Revenue Cycle Management (RCM) workflows have not yet been updated — and because these losses arrive as downcodes rather than denials, they never surface in standard reporting.
For a neurology group billing $2.5M to $5M per 12 months, the combined exposure across all three code families reaches $180,000 to $420,000 in per-12-months revenue at risk. For a foundational review of how CPT codes drive neurology reimbursement, see Understanding CPT and ICD-10 Codes for Neurology Billing.
What Changed in 2026 — and Why Neurology Is the Primary Target
Three separate actions converged this year: AMA revised documentation requirements for neurobehavioral and neuropsychological testing codes; CMS finalized stricter sequential infusion documentation standards under the 2026 Physician Fee Schedule; and the long-term EEG monitoring 95700 series entered full MAC LCD enforcement, ending the transitional grace period that ran from 2023 through 2025. Claims that passed automated review under 2025 transitional guidance are now subject to full compliance scrutiny. For how these changes compound with the MPFS conversion factor reduction, see How Are the 2026 Medicare RVU Adjustments Reducing Neurology Reimbursement?
The Three Code Families at Risk: 2026 Changes and Financial Exposure
Cognitive and Neurobehavioral Testing (96116, 96130–96133, 96136–96139)
The 2026 AMA CPT clarification requires that 96116 (neurobehavioral status exam) be billed only when the physician performs the exam face-to-face with time explicitly documented. When 96116 and 96136 (computer-administered testing) appear on the same date of service without documentation separating physician examination work from technician-administered testing, MA plans auto-downcode 96116 to 96138 — generating a loss of $85 to $140 per session with no denial issued.
96130/96131 (neuropsychological testing evaluation) require a standalone interpretation report; when it is embedded in the administration record, payers treat the two services as duplicative and bundle them.
| CPT Code | Description | 2026 Risk | Per-Session Revenue at Risk |
|---|---|---|---|
| 96116 | Neurobehavioral status exam, first hour | Auto-downcode to 96138 when physician vs. technician time not separated | $85–$140 |
| 96121 | Neurobehavioral status exam, additional hour | Denied when technician performed any component without supervision note | $60–$95 |
| 96130 | Neuropsychological testing evaluation, first hour | Denied when interpretation is embedded in administration record | $95–$130 |
| 96136 | Computer-administered testing, first 30 min | Denied when physician order and co-signature are absent | $45–$70 |
Financial exposure: 75 sessions per month at mid-range downcode rate = $108,000 per 12 months in undetectable revenue loss.
Therapeutic Infusion Codes (96365–96368)
CMS finalized stricter sequential infusion documentation requirements for 96366 (additional sequential infusion, same substance) and 96367 (additional sequential infusion, new substance) under the CMS MLN Infusion Therapy Services guidance. Three specific failure patterns are generating denials and compliance exposure in 2026:
- Pattern A — Concurrent billed as sequential: Two agents running simultaneously coded under 96366 instead of 96368, creating post-payment audit recoupment risk at $180 to $240 per encounter
- Pattern B — Add-on without primary service time: 96366 billed without documented start/stop times for the primary 96365 interval — payers bundle the add-on into the primary code at no additional reimbursement
- Pattern C — 96367 without substance-level medical necessity: MA plan review now requires a distinct clinical note (not a templated order) explaining the therapeutic necessity of each sequential agent
| CPT Code | Description | 2026 Risk | Per-Encounter Revenue at Risk |
|---|---|---|---|
| 96365 | Initial infusion, up to one hour | Add-on codes bundled when start/stop times absent | Indirect — enables add-on denial |
| 96366 | Additional sequential infusion, same substance | Bundled into 96365 without discrete interval documentation | $55–$90 |
| 96367 | Additional sequential infusion, new substance | Denied without substance-specific medical necessity note | $70–$120 |
| 96368 | Concurrent infusion | Overcoded when documented as sequential — compliance exposure | Recoupment risk |
Financial exposure: 55 sessions per month = $126,000 per 12 months in combined underpayment and compliance risk. For how MBC structures infusion billing oversight, see Neurology Billing Services.
Long-Term EEG Monitoring (95700 Series)
The 95700 series is now under full MAC Local Coverage Determination enforcement. The most common 2026 downcode is 95716 ? 95715 — monitored LTVE with video reduced to without video — when video monitoring is present in the recording system but not separately documented as a physician-ordered component of the monitoring plan. The reimbursement difference is $90 to $150 per monitoring day.
| CPT Code | Description | 2026 Risk | Per-Day Revenue at Risk |
|---|---|---|---|
| 95716 | LTVE, with video, monitored | Downcode to 95715 when video not physician-ordered in documentation | $90–$150 |
| 95720 | LTVE, with video, continuously monitored | Downcode when physician review timestamping absent from record | $110–$170 |
| 95706 | LTVE, without video, prolonged | Denied when start/stop times inferred rather than documented | $60–$95 |
Financial exposure: 30 monitoring days per month = $54,000 per 12 months — none appearing as denials. For how Revenue Integrity intersects with diagnostic coding compliance, see Mastering 2024 Neurology Billing Guidelines for Reimbursement.
Combined 2026 CPT Audit Exposure at a Glance
| Risk Category | Monthly Volume (Mid-Range) | Per-12-Months Revenue at Risk |
|---|---|---|
| Cognitive testing downcode (96116 ? 96138) | 75 sessions | $108,000 |
| Infusion add-on bundling (96366 / 96367) | 55 sessions | $126,000 |
| Monitoring downcode (95716 ? 95715) | 30 monitoring days | $54,000 |
| Total combined exposure | $288,000 |
None of this $288,000 appears on a denial report — it surfaces as flat collections despite stable volume, a pattern consistent with MGMA benchmarking data showing the average neurology practice collecting 83–88% of collectible revenue versus the 94–97% top-performer threshold, and one that denial root-cause engineering identifies within 30 days of a targeted billing audit.
MBC Spotlight: 2026 CPT Audit Readiness for Neurology
MBC's Neurology Billing Services include active remittance analysis comparing paid amounts against fee schedule rates for every 96116, 96366, 95716, and 95720 claim — catching accepted-but-downcoded revenue that standard Denial Management workflows never flag. Our system-agnostic platform applies pre-submission documentation checklists at charge entry, and our dedicated account manager tracks payer variance detection gaps on MA plan remittances monthly.
For neurology practices with aged Old AR Recovery exposure on cognitive testing or infusion claims from 2024–2025 billing cycles still within the appeal window, MBC's retrospective audit protocol recovers the Yield EBITDA gap between what was paid and what the correct code warranted. Visit our Old AR Recovery Services page for details. MBC's Pricing Structure is percentage-based with no setup fees — full MBC's fee structure at our Pricing page.
Practices completing MBC's Complimentary 90-Day AR Diagnostic identify an average of $90,000 to $280,000 in neurology CPT audit gaps before a single appeal is filed.
Request Your Free Revenue Diagnostic
If your neurology practice is billing cognitive assessments, infusion therapy, or long-term EEG monitoring under 2025 protocols, your 2026 compliance exposure is active. Request Your Free Revenue Diagnostic and let MBC's specialists audit your cognitive, infusion, and monitoring claims before the appeal window closes. Contact us at info@medicalbillersandcoders.com or call 888-357-3226.
